Table 3.
Fold reduction in PRNT50 titres in comparison to wild type virus or to Omicron BA.2 virus in vaccine or infection cohorts.
| Exposure group | fold reduction vs WT | fold reduction vs BA.2 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WT | BA1 | BA2 | BA2.12.1 | BA4 | BA5 | WT | BA1 | BA2 | BA2.12.1 | BA4 | BA5 | |
| BNT162b2 (3 doses) | 1.0 | 4.8 | 3.4 | 4.6 | 11.3 | 15.5 | 0.3 | 1.4 | 1.0 | 1.4 | 3.4 | 4.6 |
| CoronaVac (3 doses) | 1.0 | 8.0 | 7.0 | 11.8 | 12.0 | 12.0 | 0.1 | 1.1 | 1.0 | 1.7 | 1.7 | 1.7 |
| CoronaVac (2 dose + BNT162b2 third dose) |
1.0 | 6.1 | 6.7 | 6.3 | 13.0 | 21.2 | 0.1 | 0.9 | 1.0 | 0.9 | 1.9 | 3.2 |
| SARS-CoV-2 (ancestral) Convalescent |
1.0 | 10.2 | 9.2 | 10.6 | 12.2 | 14.0 | 0.1 | 1.1 | 1.0 | 1.2 | 1.3 | 1.5 |